Rezolute logo
Rezolute RZLT
$ 3.94 1.87%
report update icon

Quarterly report 2026-Q4
added 09-24-2026

Rezolute Income Statement 2026-2010 | RZLT

Annual Income Statement Rezolute

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Market Cap

409 M 586 M 248 M 79.3 M 28.2 M 30.7 K 99.4 M 18.8 M 21.2 M 45.4 M 25.3 M 33.5 M 17.4 M 31.6 M - - -

Shares

104 M 76 M 51.5 M 51.2 M 18.2 M 7.67 K 5.87 M 1.78 M 1.11 M 826 K 495 K 419 K 188 K 124 K - - -

Historical Prices

3.94 7.71 4.82 1.55 1.55 4.78 12 5.75 4.5 44.2 50 73 62.5 159 - - -

Net Income

-77.6 M -74.4 M -68.5 M -51.8 M -41.1 M -20.9 M -20.3 M -30.4 M -29.9 M -20.3 M -14.9 M -11.4 M -9.73 M -6.73 M -49.3 K - -301 K

Gross Profit

- - - - - - - - - - - - - - -4.84 K - -

Operating Income

-83 M -79.9 M -70.4 M -56 M -41.8 M -22.9 M -20.5 M -25.9 M -28.7 M -20.3 M -15 M -10.7 M -5.18 M -6.11 M - -393 K -

Interest Expense

- - - - - 375 K - 4.96 M 689 K 1.6 K 5.04 K 6.73 K 4.23 M 569 K - 204 K -

EBITDA

-82.9 M -79.9 M -70.4 M -56 M -41.8 M -22.9 M -20.5 M -25.8 M -25.3 M -19.2 M -14.2 M -10.6 M -5.16 M -6.11 M -45.5 K - -

Operating Expenses

83 M 79.9 M 70.4 M 56 M 41.8 M 22.9 M 20.5 M 25.9 M 26.4 M 20.3 M 15 M 10.7 M 5.18 M 6.11 M 42.7 K - -

General and Administrative Expenses

29.2 M 18.4 M 14.7 M 12.2 M 9.36 M 7.91 M 6.07 M 6.82 M 9.1 M 8.23 M 5.5 M 6 M 5.13 M 6.1 M 42.7 K - -

All numbers in USD currency

Quarterly Income Statement Rezolute

2026-Q4 2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- 104 M 104 M 103 M 104 M 103 M 87 M 70 M 69.9 M 69.7 M 53.2 M 50.8 M 51.4 M 51.4 M 36.8 M 51.4 M 51.4 M 50.5 M 33.6 M 17.2 M 15.7 M 8.51 M 12.1 M 8.35 M 8.04 M 5.87 M 6.96 K 5.87 K 5.87 K 5.41 K 293 K 270 K 62.1 K 62.2 K 62.1 M 62.2 M 53.8 M 52.9 M 53.8 M 52.9 M 40.8 M 35.4 M 40.8 M 35.4 M 24.3 M 24.3 M 24.3 M 24.3 M 18.9 M 18.1 M 18.9 M 18.1 M 6.67 M 6.67 M 6.67 M 40 M 24.6 M 4.1 M 35.3 M 3.84 M 35.3 M 3.84 M 3.84 M 3.84 M

Net Income

- -16.2 M -22.8 M -18.2 M -22.8 M -18.2 M - -18.9 M -15.7 M -15.4 M - -17 M -13.9 M -14.5 M - -15.7 M -13.6 M -9.83 M -23.4 M -11.2 M -12.6 M -7.84 M -20.4 M 20.9 M -7.1 M -3.62 M -7.1 M -3.62 M -6.67 M -5.08 M -6.67 M -5.08 M -4.16 M -3.36 M -4.16 M -3.37 M -5.72 M -6.68 M -5.72 M -6.68 M -4.89 M -3.82 M -4.89 M -3.82 M -4.07 M -3.29 M -4.07 M -3.29 M -2.94 M -2.21 M -2.94 M -2.21 M -1.82 M -820 K -1.82 M -820 K -538 K -631 K -9.31 K -177 K -8 K -7.39 K -8 K -7.39 K

Operating Income

- -17.4 M -24.2 M -19.8 M -24.2 M -19.8 M - -20 M -17.1 M -16.9 M - -16.2 M -15.2 M -15.9 M - -17.1 M -14.4 M -10.2 M -24.6 M -10.8 M -12.1 M -7.64 M -19.8 M -5.48 M -7.15 M -3.62 M -7.15 M -3.62 M -6.72 M -5.18 M -6.72 M -5.18 M -3.16 M -2.56 M -3.16 M -2.56 M -5.75 M -6.72 M -5.75 M -6.72 M -4.89 M -3.82 M -4.89 M -3.82 M -4.07 M -3.3 M -4.07 M -3.3 M -3.07 M -2.24 M -3.07 M -2.24 M -650 K -701 K -650 K -701 K -500 K -543 K - -94.6 K - - - -

Interest Expense

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 42.8 K 1.29 M 911 K 1.29 M 912 K 147 - 147 - - 1.6 K - 1.6 K 1.38 K 1.61 K 1.38 K 1.61 K 2.3 K 500 2.3 K 500 623 K 165 K 623 K 165 K 109 K 105 K - 91.7 K - - - -

EBITDA

- -17.3 M -24.2 M -19.8 M - -19.8 M - - - -16.9 M - - - -15.9 M - - -14.4 M -10.2 M -24.6 M -10.8 M -12.1 M -7.64 M -19.8 M -5.48 M -7.15 M -3.62 M -7.15 M -3.62 M -6.72 M -5.17 M -6.71 M -5.17 M -3.15 M -2.54 M -3.12 M -2.3 M -5.48 M -6.45 M -5.22 M -6.45 M -4.61 M -3.56 M -4.61 M -3.56 M -3.92 M -3.23 M -3.92 M -3.23 M -3.04 M -2.21 M -3.01 M -2.21 M -649 K -700 K -648 K -700 K -500 K -543 K - -94.6 K - - - -

Operating Expenses

- 17.4 M 24.2 M 19.8 M 24.2 M 19.8 M - 20 M 17.1 M 16.9 M - 16.2 M 15.2 M 15.9 M - 17.1 M 14.4 M 10.2 M 24.6 M 10.8 M 12.1 M 7.64 M 19.8 M 5.48 M 7.15 M 3.62 M 7.15 M 3.62 M 6.72 M 5.18 M 6.72 M 5.18 M 3.16 M 2.56 M - 2.56 M 5.75 M 6.72 M 12.5 M 6.72 M 4.89 M 3.82 M 4.89 M 3.82 M 4.07 M 3.3 M 4.07 M 3.3 M 3.07 M 2.24 M 3.07 M 2.24 M 650 K 701 K 650 K 701 K 500 K 543 K 9.31 K 94.6 K 8 K 7.39 K 8 K 7.39 K

General and Administrative Expenses

- 5.95 M 9.87 M 6.67 M 9.87 M 6.67 M - 4.74 M 4.45 M 4.19 M - 3.81 M 3.16 M 3.7 M - 2.91 M 3.45 M 2.51 M 5.96 M 2.07 M 2.7 M 1.87 M 4.56 M 1.72 M 2.66 M 1.28 M 2.66 M 1.28 M 1.68 M 1.94 M 1.68 M 420 K 292 K 239 K 531 K 414 K 318 K 328 K 318 K 328 K 302 K 257 K 302 K 257 K 198 K 205 K 198 K 205 K 184 K 356 K 184 K 553 K 80.5 K 17.4 K 7.54 K 19.5 K 23.2 K 5.01 K 9.31 K 3.53 K 8 K 7.39 K 8 K 7.39 K

All numbers in USD currency

The income statement is one of the three key financial reports of a company Rezolute (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
AnaptysBio AnaptysBio
ANAB
$ 51.7 1.83 % $ 1.5 B usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 3.73 3.61 % $ 258 M britainBritain
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
$ 1.89 0.53 % $ 107 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Evelo Biosciences Evelo Biosciences
EVLO
- -14.46 % $ 27.9 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.52 1.17 % $ 6.21 B israelIsrael
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 61.35 0.06 % $ 11.8 B usaUSA
Benitec Biopharma Benitec Biopharma
BNTC
$ 9.64 0.46 % $ 449 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 99.26 0.81 % $ 24 B germanyGermany
Freeline Therapeutics Holdings plc Freeline Therapeutics Holdings plc
FRLN
- - $ 384 M britainBritain
Genocea Biosciences Genocea Biosciences
GNCA
- -15.0 % $ 3.04 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 3.63 3.93 % $ 795 M britainBritain
Amryt Pharma plc Amryt Pharma plc
AMYT
- - $ 621 M britainBritain
G1 Therapeutics G1 Therapeutics
GTHX
- - $ 370 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.17 0.46 % $ 3.57 M israelIsrael
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 14.24 0.35 % $ 1.27 B usaUSA
C4 Therapeutics C4 Therapeutics
CCCC
$ 3.03 0.3 % $ 251 M usaUSA
Codexis Codexis
CDXS
$ 1.37 1.45 % $ 119 M usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 2.61 0.38 % $ 497 M usaUSA
AbbVie AbbVie
ABBV
$ 265.12 0.09 % $ 469 B usaUSA
Humanigen Humanigen
HGEN
- -81.12 % $ 4.28 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.17 1.48 % $ 137 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 12.65 2.76 % $ 3.78 B canadaCanada
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 5.43 2.65 % $ 288 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 31.48 1.16 % $ 2.09 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 4.12 1.98 % $ 50.3 M israelIsrael
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 2.08 0.48 % $ 5.43 M usaUSA
IGM Biosciences IGM Biosciences
IGMS
- - $ 76.9 M usaUSA
IMV IMV
IMV
- - $ 13.1 M canadaCanada
Kinnate Biopharma Kinnate Biopharma
KNTE
- - $ 123 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Karuna Therapeutics Karuna Therapeutics
KRTX
- - $ 12.2 B usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
$ 1.15 1.67 % $ 13 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 22.64 0.85 % $ 717 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 118.51 4.93 % $ 12.3 B usaUSA
Chimerix Chimerix
CMRX
- - $ 756 M usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 7.45 0.19 % $ 99.2 M usaUSA
Curis Curis
CRIS
$ 0.88 0.85 % $ 11.6 M usaUSA
CorMedix CorMedix
CRMD
$ 7.77 1.04 % $ 560 K usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 55.7 0.23 % $ 5.01 B schweizSchweiz
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
$ 11.8 8.21 % $ 932 M usaUSA
Champions Oncology Champions Oncology
CSBR
$ 4.95 0.38 % $ 68.5 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.88 0.62 % $ 935 M canadaCanada
Cue Biopharma Cue Biopharma
CUE
$ 32.85 3.6 % $ 3.11 B usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
$ 1.72 2.38 % $ 13.8 M usaUSA